Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism

Basit Öğe Kaydı
dc.contributor.authorAkbaba, Gülhan
dc.contributor.authorIşık, Serhat
dc.contributor.authorAteş Tütüncü, Yasemin
dc.contributor.authorÖzu?uz, Ufuk
dc.contributor.authorBerker, Dilek
dc.contributor.authorGüler, Serdar
dc.date.accessioned2019-05-13T08:57:31Z
dc.date.available2019-05-13T08:57:31Z
dc.date.issued2013
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractAim: To evaluate and compare the efficacy of alendronate sodium (ALN) and raloxifene (RLX) for the management of primary hyperparathyroidism (PHPT) in postmenopausal female patients (pts) with osteoporosis. Methods: Twenty-four postmenopausal women with osteoporosis who were diagnosed with PHPT, but refused the option of surgery, were enrolled. Participants were sequentially randomized into two groups: an ALN-group of 12 pts (70 mg/week) and a RLX-group of 12 pts (60 mg/day). The control group consisted of 10 pts with PHPT who did not have any indications for surgery. Results: The decrease in ionized calcium levels was significantly more pronounced in the ALN group compared to the RLX and control groups (p<0.001). In terms of difference from baseline in bone mineral density (BMD) of the lumbar area in percentages over a period of 12 months, pts in the ALN and RLX groups both showed statistically significant improvements compared to pts in the control group (control vs ALN, p<0.001; control vs RLX, p<0.001). BMD measurements of the femoral and radial areas were comparable in all three groups. Conclusions: ALN and RLX may improve bone density in the lumbar area of osteoporotic post-menopausal women with PHPT. The more significant decrease in serum calcium levels which was observed in the ALN group compared to both RLX and control groups, suggests that ALN could be used for the short-term control of calcium levels in patients awaiting surgery. ©2013, Editrice Kurtis.
dc.identifier.citationAkbaba, G., Işık, S., Ateş Tütüncü, Y., Özuğuz, U., Berker, D., Güler, S. (2013). Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism. Journal of Endocrinological Investigation, 36(11), 1076-1082.
dc.identifier.doi10.3275/9095
dc.identifier.endpage1082en_US
dc.identifier.issn0391-4097
dc.identifier.issue11en_US
dc.identifier.scopusqualityQ1
dc.identifier.startpage1076en_US
dc.identifier.urihttps://doi.org/10.3275/9095
dc.identifier.urihttps://hdl.handle.net/11491/946
dc.identifier.volume36en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.relation.ispartofJournal of Endocrinological Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAlendronate Sodiumen_US
dc.subjectBone Mineral Densityen_US
dc.subjectOsteoporosisen_US
dc.subjectPrimary Hyperparathyroidismen_US
dc.subjectRaloxifeneen_US
dc.titleComparison of alendronate and raloxifene for the management of primary hyperparathyroidism
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu